Sansanima, a University of Sheffield spinout, is on a mission to eliminate animal testing in clostridial medicine production. The company’s innovative cell-based assay platform precisely replicates the physiological intoxication processes of tetanus and botulinum toxins, providing manufacturers with a humane, reproducible alternative that satisfies regulatory requirements across global markets.

With patents already secured across major markets, including the US, EU, South Korea, and Japan, Sansanima has achieved significant validation milestones, including MHRA approval for botulinum toxin type B testing and positive feedback from international vaccine producers. The company’s technology addresses growing ethical concerns and regulatory pressure to reduce animal testing and offers manufacturers a more consistent, scalable, and cost-effective solution for ensuring product safety and efficacy in this critical therapeutic area.